Preview

Кардиоваскулярная терапия и профилактика

Расширенный поиск

НАРУШЕНИЯ УГЛЕВОДНОГО ОБМЕНА И ИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦА: ПРОГНОСТИЧЕСКОЕ ЗНАЧЕНИЕ, ЭФФЕКТИВНОСТЬ РЕВАСКУЛЯРИЗАЦИОННЫХ ВМЕШАТЕЛЬСТВ

https://doi.org/10.15829/1728-8800-2013-3-79-84

Полный текст:

Аннотация

В обзоре литературы представлены данные о распространенности и прогностической значимости нарушений углеводного обмена: сахарного диабета (СД) 2 типа, предиабета — гипергликемии натощак и нарушенной толерантности к глюкозе, у больных ишемической болезнью сердца (ИБС). Изложены результаты крупных исследований о сравнительной эффективности современной медикаментозной терапии и методов реваскуляризации миокарда — чрескожных коронарных вмешательств и коронарного шунтирования у больных ИБС с СД. 

Об авторах

Л. В. Кремнева
ГАУЗ ТО «Тюменский институт терапии», Тюмень
Россия

д. м.н., ведущий научный сотрудник

Тел.: (3452) 29–43–44 



Т. С. Пурсанова
ГБОУ ВПО «Тюменская государственная медицинская академия» Министерства здравоохранения РФ
Россия
аспирант


О. В. Абатурова
ГБОУ ВПО «Тюменская государственная медицинская академия» Министерства здравоохранения РФ
Россия
д. м.н., профессор кафедры ФПК и ППС


Список литературы

1. Medical and demographical parameters of Russian Federation — 2006 year. Statistical materials. M. 2007; 188 р. Russian (Медико- демографические показатели Российской Федерации — 2006 год. Статистические материалы. Москва 2007; 188 с).

2. Dedov II, Shestakova MV. Diabetes mellitus is global medical and social probleme of modernity. Consilium Medicum 2001; 12: 5–8. Russian (Дедов И. И., Шестакова М. В. Сахарный диабет — глобальная меди- ко-социальная проблема современности. Consilium Medicum 2001; 12: 5–8).

3. Suntsov UI, Bolotskaya LL, Maslova OV, Kazakov IV. Epidemiology of diabetes mellitus and prognosis of its extent in Russian Federation. Diabetes mellitus 2011; 1: 15–8. Russian (Cyнцов Ю. И., Болотская Л. Л., Маслова О. В., Казаков И. В. Эпидемиология сахарного диабе- та и прогноз его распространенности в Российской Федерации. Сахарный диабет 2011; 1: 15–8).

4. Guidelines on diabetes, pre-diabetes and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88–136.

5. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782–7.

6. Juutilainen A. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care 2004; 27: 2898–904.

7. Panova EI, Korneva KT. Diabetes mellitus of 2d type and unfavourable prognostically faetors. Clinical medicine 2010; 6: 43–7. Russian (Панова Е. И., Корнева К. Т. Сахарный диабет 2-го типа и прогностиче- ски неблагоприятные факторы. Клиническая медицина 2010; 6: 43–7).

8. Alexandrov AA, Yadrihinskaya MK, Kuharenko CC. Atrial fibrillation: new type of diabetes mellitus in 21 century. Diabetes mellitus 2011; 1: 53–60. Russian (Александров А. А., Ядрихинская М. К., Кухаренко С. С. Мерцательная аритмия: новый лик сахарного диабета в ХХI веке. Сахарный диабет 2011; 1: 53–60).

9. Genuth S, Alberti KG, Benett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26 (11): 3160–7.

10. Du XT, de Galan B, Abadir E, et al. Risk of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE Study. Eur Heart J 2009; 30 (9): 1128–35.

11. Cook S, Windecker S. Revascularisation of coronary diabete in patients with diabetes mellitus. Swiss Med WKLY 2009; 139: 654–64. www.smw.ch.

12. Marso SP, Lincoff M, Ellis SG, et al. Optimizing the percutaneous outcome for patients with diabetes mellitus. Results of the EPYSTENT Diabetic Substudy. Circulation 1999; 100: 2477–84.

13. Marks JB, Raskin P. Сardiovascular risk in diabetes. J Diabet Complicat 2000; 14: 108–15.

14. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS). Lancet 1998; 352: 837–53.

15. Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study. Circulation 1999; 99: 2626–32.

16. McGuire DK, Emanuelsson H, Granger CB, et al. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the CUSTO-IIb study. Custo-IIb Investigators. Eur Heart J 2000; 21: 1750–8.

17. Bhadriraju S, Cannon CP, De Franco AC, et al. Association between blood glucose and long term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial. Circulation 2003; 108: 1475.

18. Bartnik M, Ryden L, Ferrari R, et al. Euro Heart Survei Investigators. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. Eur Heart J 2004; 25: 1880–90.

19. Franklin K, Goldberg RJ, Spenser F, et al. The GRACE Investigators. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med 2004; 164: 1357–463.

20. Malmberg K, Ryden L, Wedel H, et al. Waldenstrom for the DIGAMI 2 Investigator Intence metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on and morbidity. Eur Heart J 2005; 26: 650–1.

21. Jacoby R, Nesto R. Acute myocardial infarction in the diabetic patients: pathophysiology, clinical course, and prognosis. JACC 1992; 20: 736–44.

22. Granger CB, Callif RM, Young S, et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The thrombolysis and angioplasty in myocardial infarction (TAMI) study group. JACC 1993; 21: 4: 920–5.

23. Saharova NC, Misheleva TO, Starodubova AV, Kislyak OA. Prevention of diabetes mellitus of 2d type and cardiovascular complications in patients with prediabetes. Medical affair 2008; 4: 2–7. Russian (Сахарова Н. С., Мышелева Т. О., Стародубова А. В., Кисляк О. А. Профилактика СД II типа и сердечно-сосудистых осложнений у пациентов с предиабетом. Лечебное дело 2008; 4: 2–7).

24. Levitan E. Gyperglycemia — is risk factor of cardiovascular diseases in patients who don, t suffer from diabetes mellitus. Arch Intern Vtd 2004; 164: 2147–55.

25. Kanaya A. Fasting hyperglycemia is not significant predictor of future cardiovascular events in women having ischemis heart disease. Ann Intern Med 2005; 142: 813–20.

26. Sorkin JD, Muller DC, Fled JL, Andres R. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Rare 2005; 28: 11: 2626–32.

27. DECODE, 1999. The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617–21.

28. Pecoraro RE, Chen MS, Porte DL. Glycosylated hemoglobin and fasting plasma glucose in the assessment of outpatient Care 1982; 5: 592–9.

29. Khaw KT, Wareham N, Luben R, et al Glycated haemoglobin, diabetes and mortality in men in Norfolk cohort of European nutrition (EPJC –Norfolk). BMJ 2001; 322 (7277): 15–8.

30. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin￾dependent diabetes mellitus. N Engl J Med 1998; 329: 977–86.

31. ADVANCE Collaborative Group et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–72.

32. Dluhy RG. McMahon G. T. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2009; 358 (2): 2630–3.

33. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129–39.

34. Svensson AM, McGuire DK, Abrahamsson P, Dellborg M. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J 2005: 26; 1255–61.

35. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention cardiovascular events: implications of the ACCORD, ADVANCE and VA Diabetes Trial. JACC 2009; 53 (3): 298–304.

36. Wijns W, Kolh Ph, Danchin N, et al. EAST Clinical Guidelines Committee: Kolh Ph., Alfieri O, Dunning J., Elia S. et al. Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Assotiation for Cardio-Thoracic Surgery (EAST). Eur Heart J 2010; 20: 2501–55.

37. The BARI Investigators. Seven — year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. JACC 2000; 35: 1122–9.

38. King SB, Kosinski AS, Guyton RA, et al. EAST Investigators. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). JACC 2000; 35: 1116–21.

39. Kurbaan AS, Borker TJ, Ilsley CD, et al. CABRI Investigators Difference in the mortality of the CABRI diabetic and nondiabetic populations and its relation to coronary artery disease and the revascularization mode. Am J Cardiol 2001; 87: 947–50.

40. Abizaid A, Costa MA, Centemero M, et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 2001; 104: 533–8.

41. Abzaiday A, Kornowski R, Mintz OS, et al. The influence of diabetes mellitus on acute clinical outcomes following coronary stent implantation. JACC 1998; 32: 584–9.

42. Carrozza JP, Ho KKL, Neimann D, et al. Diabetes mellitus is associated with adverse 6-month angiographic and clinical outcome following coronary stenting. Circulation 1998; 98: 1–79.

43. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-elutini stents one-year angiographic and Intravascular ultrasound follow-up. Circulation 2001; 104: 2007–11.

44. Sedlis SP, Morrison DA, Lorin JD, et al. Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angins and risk factors for adverse outcome with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. JACC 2002; 40: 1555–66.

45. Lee MS, Yang T, Dhoot J, et al. Meta-analysis of studies comparimg coronary artery bypass grafting with drug-eluting stenting in patients with diabetes mellitus. Am J Cardiol 2010; 105 (11): 1540–4.

46. Serruys PW, Morice MC, Kappetein P, et al. For the SYNTAX Invastigators. Percutaneous coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease. N Engl J Med 2009; 360: 10: 961–72.

47. Banning AP, Westaby S, Morice MC, et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcome with cardiac surgery and paclitaxel — eluting stents. JACC 2010; 55 (11): 1067–75.

48. Fryе RL, August P, Brooks MM, et al. for the BARY 2D Study Group. A Randomized Trial of Therapies for Tupe 2 Diabetes and Coronary Artery Disease. N Engl J Med 2009; 24 (360): 2503–15.

49. Kapur A, Hall RL, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetes patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. JACC 2010; 2: 55: 432–40.

50. Feit F, Brooks MM, Sopko G, et al. Long- term clinical outcome in the bypass Angioplasty Revascularozation Invastigation Registry. Circulation 2000; 101: 2795–802.

51. Alexandrov AA. Diabetes mellitus and interventional cardiology: if to tell the truth… CONSILIUM MEDICUM 2009; 12 (11): 9–17. Russian (Александров А. А. Сахарный диабет и интервенционная кардиология: если к правде святой … CONSILIUM MEDICUM 2009; 12 (11): 9–17).

52. Rydern L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre￾diabetes and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88–136.


Для цитирования:


Кремнева Л.В., Пурсанова Т.С., Абатурова О.В. НАРУШЕНИЯ УГЛЕВОДНОГО ОБМЕНА И ИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦА: ПРОГНОСТИЧЕСКОЕ ЗНАЧЕНИЕ, ЭФФЕКТИВНОСТЬ РЕВАСКУЛЯРИЗАЦИОННЫХ ВМЕШАТЕЛЬСТВ. Кардиоваскулярная терапия и профилактика. 2013;12(3):79-84. https://doi.org/10.15829/1728-8800-2013-3-79-84

For citation:


Kremneva L.V., Pursanova T.S., Abaturova O.V. CARBOHYDRATE METABOLISM DISORDERS AND CORONARY HEART DISEASE: PROGNOSTIC VALUE AND REVASCULARISATION EFFECTIVENESS. Cardiovascular Therapy and Prevention. 2013;12(3):79-84. (In Russ.) https://doi.org/10.15829/1728-8800-2013-3-79-84

Просмотров: 143


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)